Pushing the Limits on the Intestinal Crossing of Metal−Organic Frameworks: An Ex Vivo and In Vivo Detailed Study
Metadatos
Mostrar el registro completo del ítemAutor
Rojas Macías, SaraEditorial
American Chemical Society
Materia
Metal-Organic Frameworks Chitosan Intestinal permeability Caenorhabditis elegans Bioavailability
Fecha
2022-03-17Referencia bibliográfica
ACS Nano 2022, 16, 5830−5838. [https://doi.org/10.1021/acsnano.1c10942]
Patrocinador
Ramon Areces Foundation project H+MOFs; M-ERA-NET CMOF.cell project - MCIN/AEI PCI2020-111998; European Union NextGenerationEU/PRTR); Comunidad de Madrid; European Regional Development Fund-FEDER 2014-2020-OE REACT-UE 1; MCIN/AEI/FEDER "Una manera de hacer Europa" RTI2018-096273-B-I00 MCIN/AEI PID2019-104228RB-I00 PID2020-112848RB-C21; Generalitat de Catalunya 2017SGR765; "Severo Ochoa" Programme for Centres of Excellence in RD SEV-2015-0496 CEX2019-000917-S; Regional Madrid funding 2017-T2/IND-5149; Juan de la Cierva incorporation JC2019-038894-I; European Union NextGenerationEU/PRTR, Multifunctional Metallodrugs in Diagnosis and Therapy Network (MICIU) RED2018-102471-TResumen
Biocompatible nanoscaled metal−organic frameworks
(nanoMOFs) have been widely studied as drug delivery systems
(DDSs), through different administration routes, with rare examples in
the convenient and commonly used oral administration. So far, the
main objective of nanoMOFs as oral DDSs was to increase the
bioavailability of the cargo, without considering the MOF intestinal
crossing with potential advantages (e.g., increasing drug availability,
direct transport to systemic circulation). Thus, we propose to address
the direct quantification and visualization of MOFs’ intestinal bypass.
For that purpose, we select the microporous Fe-based nanoMOF, MIL-
127, exhibiting interesting properties as a nanocarrier (great
biocompatibility, large porosity accessible to different drugs, green
and multigram scale synthesis, outstanding stability along the
gastrointestinal tract). Additionally, the outer surface of MIL-127
was engineered with the biopolymer chitosan (CS@MIL-127) to improve the nanoMOF intestinal permeation. The
biocompatibility and intestinal crossing of nanoMOFs is confirmed using a simple and relevant in vivo model, Caenorhabditis
elegans; these worms are able to ingest enormous amounts of nanoMOFs (up to 35 g per kg of body weight). Finally, an ex vivo
intestinal model (rat) is used to further support the nanoMOFs’ bypass across the intestinal barrier, demonstrating a fast
crossing (only 2 h). To the best of our knowledge, this report on the intestinal crossing of intact nanoMOFs sheds light on the
safe and efficient application of MOFs as oral DDSs.